1 / 26

IMDA networking event

IMDA networking event. Barry Heavey Head of Life Sciences 2/10/14. Recent investment announcements 2013/2014.

jalena
Download Presentation

IMDA networking event

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. IMDA networking event Barry Heavey Head of Life Sciences 2/10/14

  2. Recent investment announcements 2013/2014 June 2014 - Establishment of an International Operations Centre in Waterford, with the creation of up to 30 highly skilled roles in supply chain, customer service, accounting, and IT positions March 2014 - Establishment of an manufacturing facility in Ireland. This newly established facility in Waterford will result in the creation of over 200 new high quality jobs May 2014 - €16 million investment in new equipment to expand its production of BD PosiFlush™ syringes - 20 additional jobs in Drogheda. June 2014 - €80m investment will build upon their existing continence care portfolio of intermittent catheter products and services including their next generation hydrophilic catheters. May 2014 - Johnson & Johnson’s two wind turbines in Cork’s lower harbour, which will support the DePuySynthes and Janssen Biologics manufacturing operations. €30m project. Dec 2013 - DePuySynthes investment of $36m in R&D in Cork, with the creation of 38 high quality jobs April. 2014 Manufacturing of biologic device combination product. 270 jobs $100M

  3. Recent Investments Announcements 2013/2014 September 2013 –officially opened a new Customer Innovation Centre in Galway, which is a centre of excellence for the development and manufacture of a number of the company’s key medical technologies for the treatment of cardiovascular and cardiac rhythm disease. Nov 2013 —officially opened state-of-the-art research and development (R&D) Innovation Centre in Limerick, Ireland. Investment of €10million. This commitment to R&D and a growing product pipeline has increased staff by 100 over the past two years and augurs well for additional employment in the future. Sept 2014 - Stryker Corporation announced plans to construct a new 44,000 square foot surgical Innovation Centre in Cork. The Innovation Centre willlfocus on R&D for products, technologies and solutions to reduce surgical procedure time and healthcare costs, New global business Services Centre Dublin Digital marketing content creation, medical writing

  4. Overview - Importance of the Irish medtechsector to government • High value manufacturing • export growth 7% CAGR ‘07-’12 • 25,000 direct employees (1.2% growth ‘07-’12) • Regional spread/impact • Strong interplay between indigenous and MNCs • R&D intensive • Stability – Irish reputation for quality in highly regulated industry • Lack of complacency – Irish reputation for operational excellence • Diversification imperative • New clinical areas: structural heart, neurotech, wound healing, respiratory • Cross sectoral opportunities; • Microelectronics & medtech, Biotech & medtech • New activities: shared services, innovation centres

  5. IDA and EI supporting the sector • Government supports for productivity gains & diversification • IDA supports for MNC in-house activity • Capital, employment, R&D, training, environmental • EI supports for overseas entrepreneurs, indigenous start-ups, HPSUs and large medtech companies • EI supports for collaborative R&D – innovation partnership • Academic collaboration • EI-IDA global sourcing initiative • Schivo and Sterimed • EI, IMDA & Skillnets support for lean/operational excellence • EI-IDA technology centres: • Irish centre for manufacturing research (ICMR) • Innovation for Ireland’s Enenrgy efficiency (I2E2) • EI Bioinnovate program and Health Innovation Hub

  6. New areas of focus • Assess the case for an advanced manufacturing research centre • Encouragement and support for B-2-B collaboration

  7. Manufacturing research Research Prioritisation: manufacturing research underfunded • EI/IDA strategy: Gap in support for medtechmfng R&D • SFI New Centre- proposal didn’t met scientific impact requirements • Technology Centre in Medical Devices- wasn’t a fit for industry • Companies willing to work together on Discrete Manufacturing • Sector agnostic • Less risk to company • Opportunity for convergence across sectors • Action Plan for Jobs 2014 • IDA/EI Joint initiative to develop business need for public research investment to support Discrete Manufacturing

  8. Discrete Manufacturing- What is this? Basic Manufacturing Differences Process Manufacturing Discrete Manufacturing Adding Distinct Items Together Blending Formula

  9. Discrete Manufacturing-Gap in Research Ecosystem? Process Manufacturing Discrete Manufacturing Adding Distinct Items Together Blending Formula PMTC

  10. Challenges for our Manufacturing Companies………………………………………………………………. • Multinationals • Positioning to win Future Manufacturing • Time lines- incoming pipeline for manufacture circa 1-5 years • Plant configuration- manufacturing for todays pipeline not tomorrows • No mandate for research if not directly operational • Regulated production environment- • Collaborate predominately with other companies to commercialise • Opportunity to build capability for future manufacturing

  11. Challenges for our Manufacturing Companies………………………………………………………………. • Sub Suppliers (SME’s and MNC’s) • Positioning to Supply Future Manufacturing Needs • Time lines-aligned with needs of innovator companies • Need to be close to the innovator to understand and deliver the future needs • Many SME’s are cash strapped for development • Opportunity to support indigenous sub supply to address future needs on shore • Opportunity to attract speciality sub suppliers from off shore

  12. B2B Industry Cluster: Commercialising B2B Innovation- Implementation………………………………………………………………. Demonstration/ Technology Cells • Strategic Technology Selection • Industrially Relevant (scale) • Skill/ Production capability uplift • De risks up front capital investment • Vendors showcasing of new mfngtechnology • Win future manufacturing • Develops sub supply base

  13. B2B Industry Cluster: Commercialising B2B Innovation- Implementation………………………………………………………………. Industry ClusterThink Tank/Incubator • Company ‘Front Doors’ • Embedding and co-located industry ‘door to door’ • Incubate and develop SME’s • HPSU- MNC visibility • ‘Drop –Zone’ for new FDI • Coached growth and development • Active engagement by regulatory, standards bodies • Sandpit for collaboration between industry and publically funded researchers

  14. B2B Industry Cluster: Commercialising B2B Innovation- Implementation………………………………………………………………. Training & National Testing Facility • Training & Test Facility • Training centre • Next Gen Manu workforce • Characterisation, Testing Facility • Analytical spin out’s, spin in’s

  15. Hypothetical Costing's- Very Preliminary Building & Equipment: circa €40m • €3m “bricks and mortar” Capex on ATB facility • 25,000ft2: host approximately 100-150 people • €2.5M – 3.5M op ex per year to run centre and fund research (people, consumables) • Circa €20M equipment budget to provide diversity & “wow factor”, €1M capex per year for equipment upgrades • An analysis of funding models is currently ongoing (Forfas) • Based on an analysis of international funding models the 1:1:1 model may be the best fit? • Core Public Funding (Operational Costs) (1) • Industry Funded (1) • Competitively won grants e.g. EU, IDA, EI, other (1) • Potential revenue streams- property rentals, VC funding, contract research

  16. Irish Times Advert- Call for Public Interest (18th July) Irish based cos engaged in the Discrete Manufacturing Value Chain? Expressions of interest sought pg7 @IrishTimespic.twitter.com/zNBqAnWsC9

  17. Strong Endorsement across both IDA and EI Clients

  18. Biopharma Cluster In Ireland More than 5,000 people employed in Biotech development and manufacturing in 2014

  19. Training & Test Facility • Training centre: 2,000 people trained in 2013 • Key determinant in recent biotech investments – no skills shortage • Practical training, real-world environment/equipment • Manufacturing technology evolving - factory of the future • Applied research/test bedding/real world • Research on product analytics is popular – non competitive • Vendor companies strongly engaged • Regulators engaged • Majority funded by cash from industry: training, contract research and collaboration

  20. $2bn in Recent Investment Wins Feb. 2013 $44m investment in Biotech campus Employs > 500 Aug. 2013 $300M investment in 400,000ft2 biotech drug substance facility Apr. 2012 $200m investment Employs > 300 April. 2014 Global supply chain, quality fill finish & packaging. 250 jobs $100M April. 2014 Manufacturing of biologic device combination product. 270 jobs $100M Apr. 2012 $500m investment in two strategic sites Respiratory and sterile fill finish Employs > 700 Jan. 2012 $350m investment Manufacturing & development 200 new jobs June. 2011 Manufacturing plant $50m/100 jobs Apr. 2012 New Biotech facility in Cork $420m/200 jobs

  21. Drug device combinations – reference sites in Ireland • Mylan: respiratory drug delivery devices • Nypro: drug delivery device Centre of excellence • Ethicon: fibrin pad manufacturing • Teva: respiratory drug delivery devices • West Pharma device contract manufacturing • Merck: autoinjector pen devices for biologics • Pfizer: prefilled syringes for vaccines • Forest labs: respiratory drug delivery devices • Allergan: various devices for drug delivery • Aerogen: Irish company developing novel inhaler technology • Amgen: sterile fill finish site with prefilled syringes • BD 2 sites in Ireland mfng syringes, pens, needles • B&L back of eye deliver device development & manufacturing

  22. Recent Investment Wins in drug-device combos • Presence in Bray (near Dublin) since 1980’s • Increasing focus on R&D in drug delivery devices • VP drug delivery and diagnostics based in Bray site • March 2013 • Second site established in Ireland • 200 new jobs: automation engineers and technicians, healthcare quality engineers and technicians, operations managers, program managers, team leaders and operators.

  23. Recent Investment Wins in drug-device combos • Mylan acquired a drug tableting site in Dublin in 2007 • Apr. 2012 announced $500m investment in Ireland • Dublin site given responsibility for respiratory drug delivery technology (dry powder inhaler) acquired from Pfizer • Up to 500 jobs to be created over 5 years

  24. Recent Investment Wins in drug-device combos • €80M investment, 270 jobs announced April 2014 • Development and manufacturing & aseptic packaging of EVARREST™ Sealant Matrix • Biomaterial pad coated in biologic product for wound healing • “The decision to manufacture EVARREST™ Sealant Matrix in Ireland was due to the unique clustering of medical device manufacturing, automation and biomanufacturing skill sets across the Johnson & Johnson companies already operating in Ireland.” Dan Wildman the Worldwide President of Ethicon Biosurgery

  25. €100M investment • 44acres Campus facility • Devices and components for biologic drug delivery • Device contacts drug – major regulatory scrutiny • 150 jobs rising to 250 • 100 construction jobs • Adds to Nypro, Teva, B&L & SanofiinWaterford

  26. To learn more log on to idaireland.com +353 1 6034285 Barry.heavey@ida.ie

More Related